The Patent Finder
TP

Teva Pharmaceutical Industries, Ltd.

Filings on record here from 2001, where this site's data begins
OverviewNotableFeesChangesFamiliesPatent listSources & methods

17 patents currently held

41 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
3 more records may belong here and await a decision; they are not counted.

The next term ends in Aug 2027. from the record

Of the 41 now held by other companies, 7 name Active Biotech AB as their current owner, and 34 more name another party. Each row says which.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
4
Ending by 2030
Aug 2027
Next term end
13
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents fee due within 90 days all others Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Injector Pen US D827,127
The most cited patent in this portfolio, cited by 72 later US patents, top 5% of design patents granted in 2018 in our data. Protection runs to 2033.
Ends Aug 2033 · High confidence
Also notable
Use of rasagilline for the treatment of restless legs syndrome US 8,946,300
Cited by 26 later US patents, top 25% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2030.
Ends Aug 2030 · High confidence
Also notable
Process for Manufacturing Glatiramer Acetate Product US 9,155,775
The largest patent family in this portfolio, 5 related applications, renewed at every maintenance window due so far. Protection runs to 2035.
Ends Jan 2035 · High confidence

Formerly held, still cited

Notable
Cited by 25 later US patents, top 10% of utility patents granted in 2019 in our data. Protection runs to 2035.
Ends Jul 2035 · High confidence
Also notable
Cited by 22 later US patents, top 25% of utility patents granted in 2018 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2035.
Ends Jun 2035 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Dec 30, 2026
    The maintenance fee for Sunitinib and Salts Thereof and Their Polymorphs (US 9,067,915) comes due Dec 30, 2026. Unpaid by Jun 30, 2027, it lapses early.
  • 2 fees due Apr 13 to 15, 2027 · next Apr 13
  • 1 fee due Sep 26, 2027
    The maintenance fee for Medical Injection Device Packaging (US 11,938,298) comes due Sep 26, 2027. Unpaid by Mar 27, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 21, 2026

What they patent

The largest of its 13 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 7,815,942Rasagiline Formulations of Improved Content Uniformity
In force
 · High confidence
In forceHigh confidence
US 9,067,915Sunitinib and Salts Thereof and Their Polymorphs
In force
 · High confidence
In forceHigh confidence
US D745,664Injector Device for a Syringe
In force
 · High confidence
In forceHigh confidence
US 8,946,300Use of rasagilline for the treatment of restless legs syndrome
In force
 · High confidence
In forceHigh confidence
US 8,539,945Dose Counter and Recording Method
In force
 · High confidence
In forceHigh confidence
US 9,626,481Dose Counter and Recording Method
In force
 · High confidence
In forceHigh confidence
US 10,232,124Re-Useable Injector Device for Syringe
In force
 · Medium confidence
In forceMedium confidence
US 11,654,140Treatment of Ocular Inflammatory Diseases Using Laquinimod
In force
 · Medium confidence
In forceMedium confidence
US D827,127Injector Pen
In force
 · High confidence
In forceHigh confidence
US 9,702,007Genetic Markers Predictive of Response to Glatiramer Acetate
In force
 · High confidence
In forceHigh confidence
10 of 17 patents shown.
Pro members see all 17.
Pro members: see all 17 patents
Also on record, not counted in the 17: 41 patents in force now held by others · 246 patents ended · 15 applications pending · 431 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited